It’s Time to Buy This Type of Healthcare Stock

Dear Wall Street Daily Reader,

Forget asking somebody Snoop-Dogg style — I’m going to tell you right now: healthcare has been a major laggard this year.

In fact, it’s in the bottom three performers out of all 11 sectors in the S&P 500.

What gives?

As I researched the answer to that question for today’s column, I uncovered a timely and burgeoning new trend that everyone should be positioning their portfolios to profit from

Simply put, it’s time to buy one of the worst-performing sectors. Now let me tell you why…

Don’t Call It a Comeback!

I’m obviously going for as many 1990s hip-hop references as I can in a single financial column. (Don’t hate!)

But now, getting back to healthcare — what’s obvious about this sector is this: the pandemic completely disrupted all semblance of normalcy

Many healthcare providers were forced to do nothing but treat COVID-19 patients.

But lo and behold, we’re (finally) coming out of the pandemic.

Case in point: the rate of hospitalizations in the US keeps plummeting.

Take a look:

Covid19 Hospitalizations

With a countrywide-reopening underway, a return to normalcy for the sector beckons.

And that’s nothing but a bullish development.

Baby Got Back(logs)

One major consequence of the pandemic was the need to put most other healthcare services on hold for 15 months to free up vital resources to save people’s lives.

Those medical needs didn’t suddenly disappear, though.

In other words, there’s a massive backlog of pent-up demand for routine healthcare services, which is now about to be released.

This is a worldwide phenomenon, too.

In England, for example, 136,200 patients had been waiting 13 weeks or more for tests at the end of April. That’s more than four times the number of backlogged patients from a year earlier.

In other words, a major headwind is turning into a tailwind.

But that’s not the only factor shifting in the healthcare sector’s favor right now…

Thank the Justices

A second major headwind is simultaneously turning into a tailwind, too.

I’m talking about the Supreme Court’s decision this month to uphold the Affordable Care Act — again.

This marks the third, and by all estimations, last challenge to the law.

The result? Concerns overhanging the industry about universal access to healthcare and, more importantly, reimbursement are about to fade into the background.

So, against this suddenly bullish backdrop, is it time to scoop up shares of hospital operators? Hell no!

Much like grocery stores, the hospital space survives on notoriously thin profit margins – four to six percent, based on American Hospital Association data going back all the way to 1981.

And if you can believe it, during the pandemic those margins crashed even lower.

A report from healthcare consulting firm Kaufman Hall revealed that the average hospital operating margins were barely positive in 2020 at 0.3%.

Even if we add in government funding from the CARES Act, it still was abysmally low at 2.7%.

And since stock prices ultimately follow earnings, that’s a terrible recipe for above-average, market-trouncing returns.

(Newsflash: That’s all we’re after here.)

But now for the good news: I’ve found an under-the-radar micro-cap healthcare stock that’s setting itself apart from the industry malaise.

Instead of operating hospitals itself, it provides vital services to hospital operators to help them improve profitability — and this solves a massive $3 billion problem.

Best of all, it boasts a coveted recurring revenue, software-as-a-service (SaaS) model, which comes with some of the highest gross margins in the world at 80%+.

Higher margins mean higher profits – and higher share prices – as sales ramp.

Ahead of the tape,

Lou Basenese

Lou Basenese
Editor and Founder, Trend Trader Daily

You May Also Be Interested In:

Louis Basenese

Louis Basenese is a professional investor, and one of the country’s leading technology analysts.

He’s spent the past 20 years analyzing emerging technologies, and developing a proven methodology to consistently profit from them.

Lou began his investment career at Morgan Stanley, where he was eventually tasked with directing over $1.5 billion in capital.

Based on...

View More By Louis Basenese